Aptose Biosciences Company Profile (NASDAQ:APTO)

About Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences logoAptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:APTO
  • CUSIP: N/A
  • Web: www.aptose.com
Capitalization:
  • Market Cap: $31.96 million
  • Outstanding Shares: 24,027,000
Average Prices:
  • 50 Day Moving Avg: $1.48
  • 200 Day Moving Avg: $1.30
  • 52 Week Range: $0.78 - $1.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.75
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.47 per share
  • Price / Book: 3.04
Profitability:
  • EBITDA: ($12,870,000.00)
  • Return on Equity: -145.95%
  • Return on Assets: -124.12%
Debt:
  • Current Ratio: 11.09%
  • Quick Ratio: 11.09%
Misc:
  • Average Volume: 262,740 shs.
  • Beta: 1.81
  • Short Ratio: 2.64
 

Frequently Asked Questions for Aptose Biosciences (NASDAQ:APTO)

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences, Inc. (NASDAQ:APTO) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.11) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.07. View Aptose Biosciences' Earnings History.

Where is Aptose Biosciences' stock going? Where will Aptose Biosciences' stock price be in 2017?

4 brokers have issued 12-month price targets for Aptose Biosciences' shares. Their forecasts range from $4.00 to $12.00. On average, they expect Aptose Biosciences' stock price to reach $7.67 in the next twelve months. View Analyst Ratings for Aptose Biosciences.

What are analysts saying about Aptose Biosciences stock?

Here are some recent quotes from research analysts about Aptose Biosciences stock:

  • 1. According to Zacks Investment Research, "Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. " (8/14/2017)
  • 2. Canaccord Genuity analysts commented, "CATB reported 3/31 cash of $38.5MM, sufficient to fund operations into Q2:18." (5/12/2017)

Who are some of Aptose Biosciences' key competitors?

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the folowing people:

  • William Glenn Rice, Chairman of the Board, President, Chief Executive Officer
  • Gregory Kwok Lee Chow, Chief Financial Officer, Senior Vice President
  • Denis R. Burger Ph.D., Independent Director
  • Erich M. Platzer M.D., Ph.D., Independent Director
  • Bradley Thompson, Independent Director
  • Mark D. Vincent M.D., Independent Director
  • Warren Whitehead, Independent Director

How do I buy Aptose Biosciences stock?

Shares of Aptose Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aptose Biosciences' stock price today?

One share of Aptose Biosciences stock can currently be purchased for approximately $1.43.


MarketBeat Community Rating for Aptose Biosciences (NASDAQ APTO)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aptose Biosciences (NASDAQ:APTO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $7.67 (436.13% upside)
Consensus Price Target History for Aptose Biosciences (NASDAQ:APTO)
Price Target History for Aptose Biosciences (NASDAQ:APTO)
Analysts' Ratings History for Aptose Biosciences (NASDAQ:APTO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/7/2017HC WainwrightUpgradeNeutral -> Buy$1.00 -> $4.00HighView Rating Details
6/8/2017Rodman & RenshawInitiated CoverageNeutral -> NeutralHighView Rating Details
5/12/2017Canaccord GenuityReiterated RatingBuy$7.00LowView Rating Details
11/16/2016Royal Bank Of CanadaLower Price TargetOutperform$18.00 -> $12.00N/AView Rating Details
10/14/2016Roth CapitalReiterated RatingBuy$8.00N/AView Rating Details
6/9/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyN/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Aptose Biosciences (NASDAQ:APTO)
Earnings by Quarter for Aptose Biosciences (NASDAQ:APTO)
Earnings History by Quarter for Aptose Biosciences (NASDAQ APTO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2($0.18)($0.11)ViewListenView Earnings Details
3/29/2016Q415($0.28)($0.38)ViewN/AView Earnings Details
11/10/2015Q315($0.33)($0.27)ViewN/AView Earnings Details
8/4/2015Q215($0.31)($0.22)ViewN/AView Earnings Details
3/3/2015Q4 2014($0.31)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aptose Biosciences (NASDAQ:APTO)
Current Year EPS Consensus Estimate: $-0.57 EPS
Next Year EPS Consensus Estimate: $-0.52 EPS

Dividends

Dividend History for Aptose Biosciences (NASDAQ:APTO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aptose Biosciences (NASDAQ:APTO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Aptose Biosciences (NASDAQ:APTO)
Latest Headlines for Aptose Biosciences (NASDAQ:APTO)
Source:
DateHeadline
americanbankingnews.com logoAptose Biosciences, Inc. (APTO) Expected to Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - October 17 at 2:30 PM
americanbankingnews.com logoAptose Biosciences, Inc. (APTO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 2:44 AM
finance.yahoo.com logoHow Does Aptose Biosciences Inc (TSX:APS) Compare To The Healthcare Sector?
finance.yahoo.com - October 2 at 3:52 PM
americanbankingnews.com logo-$0.12 Earnings Per Share Expected for Aptose Biosciences Inc (APTO) This Quarter
www.americanbankingnews.com - September 28 at 10:38 PM
americanbankingnews.com logoAnalyzing CytRx Corporation (CYTR) and Aptose Biosciences (APTO)
www.americanbankingnews.com - September 21 at 4:26 PM
americanbankingnews.com logoAptose Biosciences (APTO) versus Its Peers Financial Analysis
www.americanbankingnews.com - September 21 at 4:28 AM
globenewswire.com logoAptose to Present at the 17th Annual Biotech in Europe Forum ... - GlobeNewswire (press release)
globenewswire.com - September 20 at 9:43 PM
seekingalpha.com logoAptose Looking Toward Human Studies - Seeking Alpha
seekingalpha.com - September 20 at 4:41 PM
americanbankingnews.com logoContrasting Icon Plc (ICLR) and Aptose Biosciences (APTO)
www.americanbankingnews.com - September 20 at 12:16 AM
finance.yahoo.com logoAptose to Present at the 17th Annual Biotech in Europe Forum
finance.yahoo.com - September 19 at 3:59 PM
americanbankingnews.com logoAptose Biosciences, Inc. (APTO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 17 at 2:50 AM
americanbankingnews.com logoPRA Health Sciences (PRAH) vs. Aptose Biosciences (APTO) Head-To-Head Survey
www.americanbankingnews.com - September 16 at 4:24 AM
finance.yahoo.com logoIs Aptose Biosciences Inc (TSX:APS) Undervalued?
finance.yahoo.com - September 13 at 5:08 PM
prnewswire.com logoBiotech Stocks on Investors' Radar -- PDL BioPharma, Progenics Pharma, Agenus, and Aptose Biosciences
www.prnewswire.com - September 13 at 2:18 AM
seekingalpha.com logoAptose Biosciences (APTO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 2:18 AM
streetinsider.com logoAptose Biosciences (APTO), CrystalGenomics Announce Issuance of US Patent for CG'806 - StreetInsider.com
www.streetinsider.com - September 12 at 4:13 PM
americanbankingnews.com logoAptose Biosciences, Inc. (APTO) Raised to "Buy" at HC Wainwright
www.americanbankingnews.com - September 10 at 8:24 AM
benzinga.com logoAnalyst Sees Near-Term Inflection Point For Aptose Biosciences, Upgrades Stock - Benzinga
www.benzinga.com - September 9 at 3:47 PM
americanbankingnews.com logoCelyad SA (CYAD) vs. Aptose Biosciences (APTO) Financial Survey
www.americanbankingnews.com - September 9 at 12:20 PM
globenewswire.com logoAptose Biosciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 5:37 PM
americanbankingnews.com logoAptose Biosciences, Inc. (APTO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 23 at 3:32 AM
finance.yahoo.com logoAptose Reports Results for the Second Quarter Ended June 30, 2017
finance.yahoo.com - August 10 at 2:15 AM
americanbankingnews.com logoAptose Biosciences, Inc. (NASDAQ:APTO) Releases Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - August 9 at 6:44 PM
americanbankingnews.com logo-$0.18 EPS Expected for Aptose Biosciences, Inc. (APTO) This Quarter
www.americanbankingnews.com - August 4 at 8:26 AM
globenewswire.com logoAptose Biosciences to Present at Canaccord Genuity 37th Annual Growth Conference - GlobeNewswire (press release)
globenewswire.com - August 3 at 5:24 PM
finance.yahoo.com logoAptose Biosciences to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 5:24 PM
finance.yahoo.com logoAptose To Release Second Quarter Ended June 30, 2017 Financial Results and Hold Conference Call on August 8, 2017
finance.yahoo.com - August 1 at 4:55 PM
americanbankingnews.com logoAptose Biosciences, Inc. (NASDAQ:APTO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 29 at 7:27 AM
businesswire.com logoReviva Pharmaceuticals Announces Addition of a New Member to its Board of Directors
www.businesswire.com - July 23 at 1:57 AM
americanbankingnews.com logoAptose Biosciences, Inc. (APTO) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - July 13 at 8:29 AM
prnewswire.com logoProstate Cancer Pipeline H1 2017 Therapeutic Key Players 3-V Biosciences Inc, 4SC AG, Actinium Pharmaceuticals ... - PR Newswire (press release)
www.prnewswire.com - July 11 at 3:22 PM
americanbankingnews.com logoAptose Biosciences, Inc. (APTO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - July 4 at 10:02 AM
benzinga.com logoBenzinga's Top Upgrades, Downgrades For June 8, 2017 - Benzinga
www.benzinga.com - June 9 at 2:21 AM
globenewswire.com logoAptose Biosciences Announces Results of Annual Meeting of Shareholders - GlobeNewswire (press release)
globenewswire.com - June 6 at 8:41 PM
streetinsider.com logoForm 6-K Aptose Biosciences Inc. For: May 11 - StreetInsider.com
www.streetinsider.com - May 12 at 4:10 PM
globenewswire.com logoAptose Reports Results for the First Quarter Ended March 31, 2017 - GlobeNewswire (press release)
globenewswire.com - May 11 at 9:03 PM
globenewswire.com logoPreclinical Data on Aptose Biosciences FLT3/BTK Inhibitor CG'806 Presented at AACR Hematologic Malignancies ... - GlobeNewswire (press release)
globenewswire.com - May 8 at 8:34 PM
streetinsider.com logoForm 6-K Aptose Biosciences Inc. For: Apr 25 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - April 25 at 3:34 PM
globenewswire.com logoAptose Biosciences to Present CG'806 Data at AACR Hematologic Malignancies Meeting - GlobeNewswire (press release)
www.globenewswire.com - April 20 at 1:42 AM
globenewswire.com logoAptose Biosciences to Present CG'806 Data at AACR Hematologic ... - GlobeNewswire (press release)
globenewswire.com - April 19 at 3:38 PM
feeds.benzinga.com logoAptose Biosciences to Present CG'806 Data at AACR Hematologic Malignancies Meeting
feeds.benzinga.com - April 19 at 8:58 AM
us.rd.yahoo.com logoAptose Reports Fourth Quarter and Year End 2016 Results
us.rd.yahoo.com - March 28 at 8:37 PM
prnewswire.com logoHow These Biotech Stocks are Faring? -- Actinium Pharma, Eleven Biotherapeutics, Neuralstem, and Aptose Biosciences - PR Newswire (press release)
www.prnewswire.com - March 27 at 8:12 AM
streetinsider.com logoAptose Biosciences (APTO) Announces Planned Departure of CBO Avanish Vellanki - StreetInsider.com
www.streetinsider.com - March 27 at 8:12 AM
seekingalpha.com logoAptose Biosciences (APTO) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 9 at 3:58 PM
feeds.benzinga.com logoAptose to Participate in Upcoming Investor Conferences
feeds.benzinga.com - March 2 at 7:54 AM
nasdaq.com logoAptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day - Nasdaq
www.nasdaq.com - February 2 at 3:38 PM
investopedia.com logoAptose Delays Lead Cancer Drug Development (APTO)
www.investopedia.com - January 27 at 4:25 PM
investopedia.com logoAptose Shifts Focus, Delays Cancer Drug Development
www.investopedia.com - January 27 at 4:25 PM
streetinsider.com logoAptose Bio (APTO) to Prioritize Development of CG'806 and Temporarily Delay Clinical Activities with APTO-253
www.streetinsider.com - January 23 at 8:50 PM

Social

Chart

Aptose Biosciences (APTO) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.